Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
18 Janvier 2023 - 5:15AM
Fulcrum Therapeutics, Inc.
® (Nasdaq: FULC),
a clinical-stage biopharmaceutical company focused on improving the
lives of patients with genetically defined rare diseases, today
announced the pricing of an underwritten public offering of
9,615,384 shares of its common stock at a public offering price of
$13.00 per share. The gross proceeds to Fulcrum from the offering,
before deducting underwriting discounts and commissions and other
estimated offering expenses, are expected to be $125 million. All
shares in the offering are to be sold by Fulcrum Therapeutics. In
addition, Fulcrum has granted the underwriters a 30-day option to
purchase up to an additional 1,442,307 shares of its common stock.
The offering is expected to close on or about January 20, 2023,
subject to customary closing conditions.
Goldman Sachs & Co. LLC, SVB Securities and Piper Sandler
& Co. are acting as joint book-running managers for the
offering. H.C. Wainwright & Co. is acting as lead manager for
the offering.
The shares are being offered by Fulcrum pursuant to an effective
shelf registration statement that was previously filed with the
U.S. Securities and Exchange Commission (the “SEC”). The offering
is being made only by means of a written prospectus and prospectus
supplement that form a part of the registration statement. A
preliminary prospectus supplement relating to and describing the
terms of the offering was filed with the SEC and is available on
the SEC’s website at www.sec.gov.
When available, copies of the final prospectus supplement
relating to the offering may be obtained from Goldman Sachs &
Co. LLC by mail at 200 West Street, New York, NY 10282, Attention:
Prospectus Department, by telephone at (866) 471-2526, or by email
at prospectus-ny@ny.email.gs.com; SVB Securities LLC, Attention:
Syndicate Department, 53 State Street, 40th Floor, Boston, MA
02109, by phone at (800) 808-7525, ext. 6105 or by email at
syndicate@svbsecurities.com; or Piper Sandler & Co., Attention:
Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN
55402, by telephone at (800) 747-3924, or by email at
prospectus@psc.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such state or jurisdiction.
About Fulcrum TherapeuticsFulcrum Therapeutics
is a clinical-stage biopharmaceutical company focused on improving
the lives of patients with genetically defined rare diseases in
areas of high unmet medical need. Fulcrum’s two lead programs in
clinical development are losmapimod, a small molecule for the
treatment of facioscapulohumeral muscular dystrophy (FSHD), and
FTX-6058, a small molecule designed to increase expression of fetal
hemoglobin for the treatment of sickle cell disease and other
hemoglobinopathies, including beta-thalassemia. Fulcrum’s
proprietary product engine FulcrumSeek™, identifies drug targets
that can modulate gene expression to treat the known root cause of
gene mis-expression.
Forward-Looking StatementsThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including, but
not limited to, statements regarding the completion of the public
offering. All such forward-looking statements are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. These risks and
uncertainties related to fluctuations in Fulcrum’s stock price,
changes in market conditions and satisfaction of customary closing
conditions related to the public offering, as well as the other
factors discussed in the “Risk Factors” section in the prospectus
supplement and registration statement referenced above and in
Fulcrum’s most recently filed Quarterly Report on Form 10-Q, as
well as other risks detailed in Fulcrum’s filings with the
Securities and Exchange Commission. There can be no assurance that
Fulcrum will be able to complete the public offering on the
anticipated terms. All information in this press release is as of
the date of the release, and Fulcrum undertakes no duty to update
this information, even if subsequent events cause its views to
change, unless required by law.
Contact:
Investors: Stephanie AscherStern IR,
Inc.stephanie.ascher@sternir.com
Media: Dee SmithExecutive Director, Corporate Communications
Fulcrum Therapeuticsdsmith@fulcrumtx.com
Fulcrum Therapeutics (NASDAQ:FULC)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Fulcrum Therapeutics (NASDAQ:FULC)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024